TABLE OF CONTENTS
1 INTRODUCTION 41
1.1 OBJECTIVES OF THE STUDY 41
1.2 MARKET DEFINITION 41
1.3 OVERVIEW OF THE EUROPE HIGH CONTENT SCREENING MARKET 41
1.4 LIMITATIONS 43
1.5 MARKETS COVERED 43
2 MARKET SEGMENTATION 47
2.1 MARKETS COVERED 47
2.2 GEOGRAPHICAL SCOPE 48
2.3 YEARS CONSIDERED FOR THE STUDY 49
2.4 CURRENCY AND PRICING 49
2.5 DBMR TRIPOD DATA VALIDATION MODEL 50
2.6 MULTIVARIATE MODELLING 53
2.7 PRODUCT TYPE LIFELINE CURVE 53
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 54
2.9 DBMR MARKET POSITION GRID 55
2.10 MARKET APPLICATION COVERAGE GRID 56
2.11 VENDOR SHARE ANALYSIS 57
2.12 SECONDARY SOURCES 58
2.13 ASSUMPTIONS 58
3 EXECUTIVE SUMMARY 59
4 PREMIUM INSIGHTS 61
4.1 PESTEL ANALYSIS 62
4.2 PORTER'S FIVE FORCES MODEL 63
5 EUROPE HIGH CONTENT SCREENING MARKET: REGULATIONS 64
6 MARKET OVERVIEW, EUROPE HIGH CONTENT SCREENING MARKET 66
6.1 DRIVERS 68
6.1.1 ADVANCEMENT IN IMAGING TECHNOLOGIES USED FOR HIGH CONTENT SCREENING 68
6.1.2 STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS 68
6.1.3 INCREASING RESEARCH ACTIVITIES ASSOCIATED WITH THE USAGE OF HIGH CONTENT SCREENING 69
6.1.4 INCREASING DRUG DISCOVERY AND DEVELOPMENT ACTIVITIES 70
6.2 RESTRAINTS 70
6.2.1 HIGH COST ASSOCIATED WITH INITIAL SETUP AND MAINTENANCE 70
6.2.2 COMPLEXITY ASSOCIATED WITH CELLULAR AND MOLECULAR SAMPLES 71
6.3 OPPORTUNITIES 72
6.3.1 GROWING NUMBER OF CONTRACT RESEARCH ORGANIZATIONS (CROS) PROVIDING HCS SERVICES 72
6.3.2 RISING INTEGRATION WITH ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN DRUG DISCOVERY AND DEVELOPMENT 72
6.3.3 INCREASING GOVERNMENT INITIATIVE AND FUNDING IN R&D 73
6.4 CHALLENGES 73
6.4.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS TO OPERATE HCS 73
6.4.2 DATA SECURITY AND DATA MANAGEMENT PROBLEMS IN HCS 74
7 EUROPE HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE 75
7.1 OVERVIEW 76
7.2 INSTRUMENTS 79
7.2.1 CELL IMAGING AND ANALYSIS SYSTEM 80
7.2.1.1 FIXED 80
7.2.1.2 MOBILE 80
7.2.2 HIGH-CONTENT AND SCREENING SYSTEM 80
7.2.2.1 FIXED 81
7.2.2.2 MOBILE 81
7.2.3 FLOW CYTOMETRY 81
7.2.4 INVITROGEN HCA ONSTAGE INCUBATOR 81
7.2.5 MICROPLATE MOVER 81
7.2.6 OTHERS 81
7.3 SOFTWARE 81
7.4 CONSUMABLES 82
7.4.1 REAGENTS & ASSAY KITS 83
7.4.2 MICROPLATES 83
7.4.3 OTHERS 83
7.5 ACCESSORIES 83
7.6 SERVICES 84
8 EUROPE HIGH CONTENT SCREENING MARKET, BY APPLICATION 86
8.1 OVERVIEW 87
8.2 PRIMARY AND SECONDARY SCREENING 90
8.2.1 INSTRUMENTS 91
8.2.2 CONSUMABLES 91
8.2.3 ACCESSORIES 91
8.2.4 SERVICES 91
8.3 TARGET IDENTIFICATION AND VALIDATION 91
8.3.1 INSTRUMENTS 92
8.3.2 CONSUMABLES 92
8.3.3 ACCESSORIES 92
8.3.4 SERVICES 93
8.4 TOXICITY STUDIES 93
8.4.1 INSTRUMENTS 94
8.4.2 CONSUMABLES 94
8.4.3 ACCESSORIES 94
8.4.4 SERVICES 94
8.5 COMPOUND PROFILING 94
8.5.1 INSTRUMENTS 95
8.5.2 CONSUMABLES 95
8.5.3 ACCESSORIES 95
8.5.4 SERVICES 96
8.6 OTHER APPLICATIONS 96
9 EUROPE HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY 97
9.1 OVERVIEW 98
9.2 MICROSCOPY 101
9.3 FLOW CYTOMETRY 101
9.4 IMMUNOHISTOCHEMISTRY 102
9.5 MASS SPECTROMETRY 103
9.6 ELISA 104
9.7 WESTERN BLOTTING 105
9.8 OTHERS 105
9.8.1 3D CELL CULTURE MODEL 106
9.8.1.1 STEROIDS 107
9.8.1.2 ORGANOIDS 107
9.8.1.3 TISSUE ON A CHIP 107
9.8.2 EXTRACELLULAR MATRIX BASED SCAFFOLD 107
9.8.3 SYNTHETIC HYDROGEL AND SCAFFOLD 107
10 EUROPE HIGH CONTENT SCREENING MARKET, BY END USER 108
10.1 OVERVIEW 109
10.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 112
10.2.1 INSTRUMENTS 112
10.2.2 CONSUMABLES 113
10.2.3 ACCESSORIES 113
10.2.4 SERVICES 113
10.3 CONTRACT RESEARCH ORGANIZATIONS 113
10.3.1 INSTRUMENTS 114
10.3.2 CONSUMABLES 114
10.3.3 ACCESSORIES 114
10.3.4 SERVICES 114
10.4 LABORATORIES 115
10.4.1 INSTRUMENTS 116
10.4.2 CONSUMABLES 116
10.4.3 ACCESSORIES 116
10.4.4 SERVICES 116
10.5 ACADEMIC AND GOVERNMENT INSTITUTES 116
10.5.1 INSTRUMENTS 117
10.5.2 CONSUMABLES 117
10.5.3 ACCESSORIES 117
10.5.4 SERVICES 117
10.6 OTHERS 118
11 EUROPE HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL 119
11.1 OVERVIEW 120
11.2 DIRECT TENDERS 123
11.3 RETAIL SALES 123
12 EUROPE HIGH CONTENT SCREENING MARKET, BY REGION 125
12.1 EUROPE 126
12.1.1 GERMANY 138
12.1.2 FRANCE 145
12.1.3 U.K. 152
12.1.4 ITALY 159
12.1.5 SPAIN 166
12.1.6 RUSSIA 173
12.1.7 TURKEY 180
12.1.8 BELGIUM 187
12.1.9 DENMARK 194
12.1.10 NETHERLANDS 201
12.1.11 SWITZERLAND 208
12.1.12 SWEDEN 215
12.1.13 POLAND 222
12.1.14 NORWAY 229
12.1.15 FINLAND 236
12.1.16 REST OF EUROPE 243
13 EUROPE HIGH CONTENT SCREENING MARKET, COMPANY LANDSCAPE 244
13.1 COMPANY SHARE ANALYSIS: EUROPE 244
14 EUROPE CONTENT SCREENING MARKET, COMPANY PROFILES 245
14.1 THERMO FISHER SCIENTIFIC INC. (2022) 245
14.1.1 COMPANY SNAPSHOT 245
14.1.2 REVENUE ANALYSIS 245
14.1.3 COMPANY SHARE ANALYSIS 246
14.1.4 PRODUCT PORTFOLIO 246
14.1.5 RECENT DEVELOPMENT 246
14.2 BD 247
14.2.1 COMPANY SNAPSHOT 247
14.2.2 REVENUE ANALYSIS 247
14.2.3 COMPANY SHARE ANALYSIS 248
14.2.4 PRODUCT PORTFOLIO 248
14.2.5 RECENT DEVELOPMENTS 248
14.3 PERKINELMER INC. (2022) 249
14.3.1 COMPANY SNAPSHOT 249
14.3.2 REVENUE ANALYSIS 249
14.3.3 COMPANY SHARE ANALYSIS 250
14.3.4 PRODUCT PORTFOLIO 250
14.3.5 RECENT DEVELOPMENTS 251
14.4 YOKOGAWA ELECTRIC CORPORATION (2022) 252
14.4.1 COMPANY SNAPSHOT 252
14.4.2 REVENUE ANALYSIS 252
14.4.3 COMPANY SHARE ANALYSIS 253
14.4.4 PRODUCT PORTFOLIO 253
14.4.5 RECENT DEVELOPMENT 253
14.5 MOLECULAR DEVICES, LLC. (A SUBSIDIARY OF DANAHER CORPORATION) 254
14.5.1 COMPANY SNAPSHOT 254
14.5.2 REVENUE ANALYSIS 254
14.5.3 COMPANY SHARE ANALYSIS 255
14.5.4 PRODUCT PORTFOLIO 255
14.5.5 RECENT DEVELOPMENT 256
14.6 AGILENT TECHNOLOGIES, INC. (2022) 257
14.6.1 COMPANY SNAPSHOT 257
14.6.2 REVENUE ANALYSIS 257
14.6.3 PRODUCT PORTFOLIO 258
14.6.4 RECENT DEVELOPMENT 258
14.7 ALIGNED GENETICS, INC. (2022) 259
14.7.1 COMPANY SNAPSHOT 259
14.7.2 REVENUE ANALYSIS 259
14.7.3 PRODUCT PORTFOLIO 260
14.7.4 RECENT DEVELOPMENT 260
14.8 ARACELI BIOSCIENCES 261
14.8.1 COMPANY SNAPSHOT 261
14.8.2 PRODUCT PORTFOLIO 261
14.8.3 RECENT DEVELOPMENT 261
14.9 AXXAM S.P.A 262
14.9.1 COMPANY SNAPSHOT 262
14.9.2 PRODUCT PORTFOLIO 262
14.9.3 RECENT DEVELOPMENT 262
14.10 BIO-RAD LABORATORIES, INC. (2022) 263
14.10.1 COMPANY SNAPSHOT 263
14.10.2 REVENUE ANALYSIS 263
14.10.3 PRODUCT PORTFOLIO 264
14.10.4 RECENT DEVELOPMENTS 264
14.11 CARL ZEISS AG 265
14.11.1 COMPANY SNAPSHOT 265
14.11.2 REVENUE ANALYSIS 265
14.11.3 PRODUCT PORTFOLIO 266
14.11.4 RECENT DEVELOPMENT 266
14.12 CORNING INCORPORATED 267
14.12.1 COMPANY SNAPSHOT 267
14.12.2 REVENUE ANALYSIS 267
14.12.3 PRODUCT PORTFOLIO 268
14.12.4 RECENT DEVELOPMENT 268
14.13 DE NOVO SOFTWARE 269
14.13.1 COMPANY SNAPSHOT 269
14.13.2 PRODUCT PORTFOLIO 269
14.13.3 RECENT DEVELOPMENTS 269
14.14 EVIDENT 270
14.14.1 COMPANY SNAPSHOT 270
14.14.2 PRODUCT PORTFOLIO 270
14.14.3 RECENT DEVELOPMENT 270
14.15 GENEDATA AG 271
14.15.1 COMPANY SNAPSHOT 271
14.15.2 PRODUCT PORTFOLIO 271
14.15.3 RECENT DEVELOPMENT 271
14.16 MERCK KGAA 272
14.16.1 COMPANY SNAPSHOT 272
14.16.2 REVENUE ANALYSIS 272
14.16.3 PRODUCT PORTFOLIO 273
14.16.4 RECENT DEVELOPMENTS 273
14.17 MILTENYI BIOTEC 274
14.17.1 COMPANY SNAPSHOT 274
14.17.2 PRODUCT PORTFOLIO 274
14.17.3 RECENT DEVELOPMENT 275
14.18 SARTORIUS AG 276
14.18.1 COMPANY SNAPSHOT 276
14.18.2 REVENUE ANALYSIS 276
14.18.3 PRODUCT PORTFOLIO 277
14.18.4 RECENT DEVELOPMENTS 277
14.19 SYSMEX CORPORATION 278
14.19.1 COMPANY SNAPSHOT 278
14.19.2 REVENUE ANALYSIS 278
14.19.3 PRODUCT PORTFOLIO 279
14.19.4 RECENT DEVELOPMENT 279
14.20 ZIFO RND SOLUTIONS 280
14.20.1 COMPANY SNAPSHOT 280
14.20.2 PRODUCT PORTFOLIO 280
14.20.3 RECENT DEVELOPMENTS 280
15 QUESTIONNAIRE 281
16 RELATED REPORTS 285

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.